Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.

Decitabine–vorinostat combo flops in paediatric B-cell acute lymphoblastic leukaemia trial

01 Jun 2020

The combination of decitabine and vorinostat does not appear to be feasible in the treatment of children with B-cell acute lymphoblastic leukaemia (B-ALL), despite encouraging response rates and pharmacodynamics, because of increased incidence of significant infectious toxicities, according to data from the TACL* pilot study.

Twenty-three children (median age, 12 years) received decitabine 15 mg/m2/dose intravenously on days 1–7 and 15–21, and vorinostat 180 mg/m2/dose orally (tablet or suspension; max dose 400 mg daily) on days 3–10 and 17–24. The chemotherapy regimen used consisted of vincristine, dexamethasone, mitoxantrone, and PEG-asparaginase.

Of the patients, six (26 percent) had refractory disease, and 11 (48 percent) had a prior allogeneic haematopoietic cell transplantation. Three patients experienced dose-limiting toxicities, which included cholestasis, steatosis, and hyperbilirubinaemia (n=1); seizure, somnolence, and delirium (n=1); and pneumonitis, hypoxia, and hyperbilirubinaemia (n=1).

Frequently reported grade 3–4 toxicities were hypokalaemia (65 percent), anaemia (78 percent), febrile neutropenia (57 percent), hypophosphatemia (43 percent), leukopenia (61 percent), hyperbilirubinemia (39 percent), thrombocytopenia (87 percent), neutropaenia (91 percent), and hypocalcaemia (39 percent). Infectious complications were also common, with 17 of 23 (74 percent) patients developing grade ≥3 infections, including invasive fungal infections in eight (35 percent).

Nine patients (39 percent) showed complete response (CR; CR + CR without platelet recovery + CR without neutrophil recovery), and five (22 percent) had stable disease. Nine patients (39 percent) were not evaluable for response, mainly due to treatment-related toxicities. Correlative pharmacodynamics revealed potent in vivo modulation of epigenetic marks, and modulation of biologic pathways associated with functional antileukaemic effects.

*Therapeutic Advances in Childhood Leukemia & Lymphoma

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 03 Aug 2018
It appears that the two-dose AS04-adjuvanted HPV-16/18 vaccine (AS04-HPV-16/18v) is the most cost-effective choice for lowering the burden of cervical cancer through universal mass vaccination for 12-year-old girls in Singapore from the perspective of the healthcare payer (MOH Singapore), according to a recent study.
30 Oct 2019
Use of regional anaesthesia-analgesia using paravertebral blocks and the anaesthetic propofol does not lead to a lower risk of breast cancer recurrence after potentially curative surgery as compared with general anaesthesia with the volatile anaesthetic sevoflurane and opioid analgesia, according to a study.
31 Oct 2019
New drug application approved by US FDA as of 16 - 31 October 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
25 Apr 2020
The human papillomavirus (HPV) DNA vaccine (GX-188E) is effective against HPV type 16/18–associated cervical intraepithelial neoplasia (CIN) 3, according to the results of a phase II trial.